KLOW: Four Peptides, One Added Anti-Inflammatory Arm

The short version

KLOW is a four-peptide research blend, most often described as KPV combined with the same three peptides found in GLOW: GHK-Cu, BPC-157, and TB-500. It is supplied as a co-dissolved mixture in a single research vial — a commonly listed composition is an 80 mg total vial made up of GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. The four peptides do not combine into a single molecule; they simply share a vial.

What KPV adds to the GLOW base is a distinct mechanism: rather than building tissue or growing blood vessels, KPV works by quieting inflammatory signaling in cells. No controlled study has ever tested the four-peptide KLOW combination — every claim about how the peptides work together is a mechanistic extrapolation from research on each peptide studied alone.

Nothing on this page is medical advice, and no dose is recommended for a person.

What it is

KLOW is a co-formulated, lyophilized blend of four chemically distinct research peptides, co-dissolved at fixed mass ratios rather than chemically bonded into one molecule. The most widely listed research-vial composition is an 80 mg total vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. KPV is a small tripeptide (lysine-proline-valine) derived from a larger hormone precursor; GHK-Cu, BPC-157 and TB-500 are the same three peptides described on the GLOW page.

No FDA-approved or pharmacopeial combination product with this composition exists. KLOW is supplied strictly as a research-chemical co-formulation, and — as with its component peptides — it is intended for laboratory research use, not human administration.

How it works

KLOW's four peptides occupy largely separate nodes of the same broad tissue-repair signaling network. KPV suppresses innate-immune inflammatory transcription (the NF-kB and MAPK pathways) and is taken up preferentially into intestinal and immune cells through the PepT1 di/tripeptide transporter ^[12]. GHK-Cu acts at a broad transcriptional level toward matrix synthesis, antioxidant defense and DNA repair, while also supplying copper that supports collagen crosslinking ^[11]. BPC-157 drives the VEGFR2/Akt/eNOS angiogenic pathway and helps stabilize the nitric-oxide system ^[4]. TB-500 (with stronger evidence available for the full-length parent protein, thymosin beta-4, than for the shorter fragment sold as TB-500) sequesters G-actin to accelerate cell migration and re-epithelialization.

The combination rationale is that these four arms address cytokine suppression, matrix remodeling, vascular supply, and cytoskeletal mobility as complementary steps in the same repair cascade. Crucially, no controlled study — in animals or humans — has tested the four-peptide KLOW blend against any single component or subset of components; every claim about the combination is an extrapolation from single-peptide research, not a finding about KLOW itself.

What the research shows

Musculoskeletal peptide landscape. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal conditions — naming TB-500/thymosin beta-4 and BPC-157 specifically — concludes that many unapproved peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight ^[8].

BPC-157 human safety pilot. A small intravenous safety study gave up to 20 mg of BPC-157 to two healthy adults and found it well tolerated, with no adverse events and no measurable changes to cardiac, hepatic, renal, thyroid or glucose biomarkers — a reassuring but extremely small safety signal ^[1].

GHK-Cu at the gene level. A 2018 gene-expression analysis found that GHK modulates roughly 31.2% of human genes at a 50%-or-greater change threshold, increasing expression of 59% of the affected genes and suppressing 41%, with particularly strong stimulation of the ubiquitin-proteasome system and of DNA-repair and antioxidant gene programs ^[11]. A separate review documents that plasma GHK levels decline with age (from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by 60) and that topical GHK-Cu increased collagen production in 70% of treated women, compared with 50% for vitamin C and 40% for retinoic acid ^[9].

KPV and inflammation. In human intestinal epithelial cells and immune cells, and in mice with induced colitis, nanomolar concentrations of KPV — taken up via the PepT1 transporter — inhibited NF-kB and MAP-kinase inflammatory signaling, reduced pro-inflammatory cytokine secretion, and reduced the severity of colitis when given orally ^[12].

Reported effects, cautions & safety

People using the four-peptide KLOW combination in research-use communities describe a profile that overlaps heavily with GLOW's, plus a theme some attribute specifically to the added KPV arm. These reports are anecdotal, not clinical evidence — drawn from online community write-ups, not any controlled study of the blend, and none specify a verified dose.

Reported benefits: faster-feeling recovery from a nagging tendon, ligament or joint injury is the most frequently described effect, alongside reduced joint and muscle pain. A broader "less inflamed" feeling — lower background achiness and better gut comfort — is often credited to the KPV component specifically, with some users describing the stack as feeling more anti-inflammatory than the KPV-free GLOW blend. Smoother, more hydrated-looking skin, improved digestion, and better sleep are also mentioned, generally less often than the recovery and inflammation themes.

Reported adverse effects, also anecdotal, not clinical evidence: injection-site redness, swelling or itching is the most commonly cited downside. Initial fatigue or lethargy in the first few days, a mild headache or light-headedness, flushing or warmth after administration, and transient nausea or mild digestive upset are also described. A counter-theme also appears in community discussion: some users report no noticeable effect at all, which discussion threads often attribute to unverified source quality rather than the mechanism itself.

Cited cautions from the literature: athletes and anyone subject to anti-doping testing should treat KLOW as off-limits because TB-500 is a fragment of thymosin beta-4, which is named on the WADA Prohibited List ^[8]. Three of the four components are pro-angiogenic, which is a theoretical concern for anyone with an active or recent cancer ^[4]. The four-peptide combination itself is untested — every component was studied alone, and BPC-157's very short elimination half-life means the components in a single co-formulated vial clear the body at mismatched rates ^[3]. Anyone with a copper-handling disorder such as Wilson's disease should be cautious about the copper load, since GHK-Cu is the mass-dominant ingredient in the canonical vial ^[9]. Anyone with autoimmune disease or an active infection should weigh the KPV arm carefully, since it works by suppressing inflammatory signaling ^[12].

Where it fits in recovery & tissue repair

KLOW is the most mechanistically complex member of this desk — it keeps every mechanism found in GLOW (matrix building, angiogenesis, cell migration) and adds a fourth, anti-inflammatory arm through KPV ^[12]. It also inherits GLOW's central limitation: none of the four peptides has been tested together in a controlled study, so the combination's benefits and risks are extrapolated from single-peptide research, not demonstrated directly. Set against BPC-157 — the single molecule with the most (if still thin) human safety data ^[1][2] — KLOW represents the frontier of mechanistic ambition on this desk, paired with the least direct evidence of any member. See the comparison page for how the three differ on evidence maturity and mechanism.